Abstract
The most accepted and least biased manner to demonstrate clinical benefit for any new treatment is to show that it conveys a survival advantage in a well-designed phase III, randomized clinical trial. However, in selected cases, an exception can be made to this sound rule. This review aims at elucidating one such example. In particular, I intend to show that when an individualized form of immunotherapy like idiotypic vaccination, which by definition is completely inactive against any tumor cells, is applied to cancer patients with indolent follicular lymphoma, a carefully crafted phase II clinical trial may be able to demonstrate clinical benefit better and more rapidly than a phase III alternative. This consideration might be rather important over the next two to three years, since the results of as many as three ongoing phase III clinical trials on idiotype vaccines are expected to be unveiled within this time frame, following the release of conclusive data of our phase II clinical trial, which is imminent.
Keywords: immunoglobulin, cell-mediated cytotoxicity (ADCC), T lymphocytes (CTLs), chemotherapy, phase II clinical trials, transfectants
Reviews on Recent Clinical Trials
Title: Clinical Benefit of Idiotype Vaccines: Too Many Trials for a Clever Demonstration?
Volume: 1 Issue: 1
Author(s): Maurizio Bendandi
Affiliation:
Keywords: immunoglobulin, cell-mediated cytotoxicity (ADCC), T lymphocytes (CTLs), chemotherapy, phase II clinical trials, transfectants
Abstract: The most accepted and least biased manner to demonstrate clinical benefit for any new treatment is to show that it conveys a survival advantage in a well-designed phase III, randomized clinical trial. However, in selected cases, an exception can be made to this sound rule. This review aims at elucidating one such example. In particular, I intend to show that when an individualized form of immunotherapy like idiotypic vaccination, which by definition is completely inactive against any tumor cells, is applied to cancer patients with indolent follicular lymphoma, a carefully crafted phase II clinical trial may be able to demonstrate clinical benefit better and more rapidly than a phase III alternative. This consideration might be rather important over the next two to three years, since the results of as many as three ongoing phase III clinical trials on idiotype vaccines are expected to be unveiled within this time frame, following the release of conclusive data of our phase II clinical trial, which is imminent.
Export Options
About this article
Cite this article as:
Bendandi Maurizio, Clinical Benefit of Idiotype Vaccines: Too Many Trials for a Clever Demonstration?, Reviews on Recent Clinical Trials 2006; 1 (1) . https://dx.doi.org/10.2174/157488706775246120
DOI https://dx.doi.org/10.2174/157488706775246120 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Specific Targeting of Akt Kinase Isoforms: Taking the Precise Path for Prevention and Treatment of Cancer
Current Drug Targets Radiotracers in Oncology
Current Radiopharmaceuticals Protein Kinase C as a Drug Target Implications for Drug or Diet Prevention and Treatment of Cancer
Current Drug Targets Cardio-vascular Activity of Catestatin: Interlocking the Puzzle Pieces
Current Medicinal Chemistry Clinical Pharmacokinetics of Systemically Administered Antimycotics
Current Clinical Pharmacology Angiogenesis: A Target for Cancer Therapy
Current Pharmaceutical Design NLRP3 Inflammasome Activation Leads to Epileptic Neuronal Apoptosis
Current Neurovascular Research Retinoids as Differentiating Agents in Oncology: A Network of Interactions with Intracellular Pathways as the Basis for Rational Therapeutic Combinations
Current Pharmaceutical Design Proteomics in the Discovery of New Therapeutic Targets for Psychiatric Disease
Current Molecular Medicine Kinetic Measurement Techniques in the Evaluation of Lipid Metabolism
Current Drug Discovery Technologies Doxorubicin-Loaded Nanoparticles: New Advances in Breast Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Benzimidazoles: An Ideal Privileged Drug Scaffold for the Design of Multitargeted Anti-inflammatory Ligands
Mini-Reviews in Medicinal Chemistry AMPA Receptor Antagonists: Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations
Current Medicinal Chemistry Generation, Subsets and Functions of Inducible Regulatory T Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Clinical Significance of Thiopurine S-Methyltransferase Gene Polymorphisms
Current Pharmacogenomics Flavonoids: A Review of Its Commercial Application Potential as Anti- Infective Agents
Current Medicinal Chemistry - Anti-Infective Agents RhoGEFs in Cell Motility: Novel Links Between Rgnef and Focal Adhesion Kinase
Current Molecular Medicine Genetic and Epigenetic Heterogeneity in Cancer: The Ultimate Challenge for Drug Therapy
Current Drug Targets